Urinary Incontinence. Biopolymer GmbH & Co.KG - Germany

Similar documents
MEDICAL POLICY SUBJECT: BULKING AGENTS FOR TREATMENT OF URINARY OR FECAL INCONTINENCE. POLICY NUMBER: CATEGORY: Technology Assessment

Periurethral Bulking Agents for the Treatment of Urinary Incontinence. Original Policy Date

Corporate Medical Policy

Medical Policy Title: Periurethral Bulking ARBenefits Approval: <Date>

Title: Zuidex versus Contigen for Stress Urinary Incontinence. Date: May 30, 2007

Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Blue Ridge Urogynecology

q7:480499_P0 6/5/09 10:23 AM Page 1 WHAT YOU SHOULD KNOW ABOUT YOUR DIAGNOSIS OF STRESS URINARY INCONTINENCE

Medical Review Criteria Invasive Treatment for Urinary Incontinence

Sep \8958 Appell Dmochowski.ppt LMF 1

MP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Fecal Incontinence. Sphincter Augmentation. Alaiyan Bilal MD Hadassah mt scopus

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

A minimally invasive treatment for stress urinary incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE

Operative Approach to Stress Incontinence. Goals of presentation. Preoperative evaluation: Urodynamic Testing? Michelle Y. Morrill, M.D.

W17: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October :00-18:00

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Post- prostatectomy Incontinence - PPI

Protocol. Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Clinical Policy: Urinary Incontinence Devices and Treatments

Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

I-STOP TOMS Transobturator Male Sling

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

THE BULKING AGENT WITH LONG-LASTING EFFECT!

MACROPLASTIQUE IMPLANTS

MP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Prolapse & Stress Incontinence

A PATIENT GUIDE TO Understanding Stress Urinary Incontinence

Surgery for stress incontinence:

Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents

RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE

New Insights in the Surgical Management of Stress Urinary Incontinence in Women

THE LONG-TERM SOLUTION FOR MALE INCONTINENCE

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction

This information is intended as an overview only

One Slim Needle One Incision. One Simple Solution for Stress Urinary Incontinence. The Difference is in the Data

What you should know about your diagnosis of incontinence

Contributor contact details

Management of recurrent stress urinary incontinence and urinary retention following midurethral sling insertion in women

6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence

*Please see amendment for Pennsylvania Medicaid at the end

FDA & Transvaginal Mesh: What Happened? What s Next?

Urinary Incontinence Treatment URINARY INCONTINENCE TREATMENT HS-080. Policy Number: HS-080. Original Effective Date: 2/2/2009

Corporate Medical Policy

Polyacrylamide Hydrogel (Bulkamid ) in Female Patients of 80 or More Years with Urinary Incontinence

Current trend in anti-incontinence surgery

Urinary Incontinence. Lora Keeling and Byron Neale

Desara TV and Desara Blue TV

Aus Artificial Uretheral Sphincter Port System

Periurethral bulking injections for stress urinary incontinence

Stress Incontinence. Susannah Elvy Urogynaecology CNS

Urethrolysis; When, Why & How. M Karram Professor of Ob/Gyn & Urology University of Cincinnati

Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women

Gamal Ghoniem,*, Jacques Corcos, Craig Comiter, Peter Bernhard, O. Lenaine Westney and Sender Herschorn

URINARY INCONTINENCE

CATRIX WOUND DRESSING CARTILAGE POWDER

Management of Female Stress Incontinence

Advanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa

MP A Prospective Evaluation of the Catheter Science M3 Mini Catheter for Patients with Prostatic Obstruction. Gaines W. Hammond Jr.

International Federation of Gynecology and Obstetrics

Pelvic Prolapse. A Patient Guide to Pelvic Floor Reconstruction

Various Types. Ralph Boling, DO, FACOG

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Female Urinary Incontinence: What It Is and What You Can Do About It

UP DATE MANAGEMENT OF URINARY INCONTINENCE IN ADULT

Medical Policy. Description/Scope. Position Statement

Injection of Urethral Bulking Agents

Incontinence; Lets talk about it. Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery

Tension Free vaginal tape. Mrs Ami Shukla, Consultant Urogynaecologist Northampton General Hospital Northampton NN1 5BD

Bladder neck bulking injection. Information for patients Gynaecology

Surgical treatment of urinary stress incontinence with tension free vaginal tape

Scottish Clinical Coding Standards

The Safety and Efficacy of a New Adjustable Single Incision Sling for Treatment of Female. Stress Urinary Incontinence Through 12-months of Follow-up

Cigna Medical Coverage Policy

1) What conditions is vaginal mesh used to commonly treat? Vaginal mesh is used to treat two different health issues in women:

Stress Urinary Incontinence in Women. What YOU can do about it...

An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence

BSUG Annual scientific update 5/6 th Nov 2012

John Laughlin 4 th year Cardiff University Medical Student

Bard: Continence Therapy. Stress Urinary Incontinence. Regaining Control. Restoring Your Lifestyle.

Efficacy and Safety of the TVT-SECUR R and Impact on Quality of Life in Women with Stress Urinary Incontinence: A 2-Year Follow-Up

Loss of Bladder Control

What the radiologists should know about US and MR findings of female urinary incontinence surgical tapes.

Information from the MAUDE Database

INSTRUCTIONS FOR USE FOR:

INCONTINENCE AND OTHER UROLOGICAL DILEMMAS DR. ANNA LAWRENCE UROLOGIST AUCKLAND HOSPITAL 161 UROLOGY

Hydrophilic Coating - Living tissue interaction

A.M.I. ATOMS System. Hydraulic system substitutes urinary sphincter function in incontinent males

Loss of Bladder Control

Incontinence. Anatomy The human body has two kidneys. The kidneys continuously filter the blood and make urine.

Desara and Desara Blue

Pelvic Health Coding & Payment Quick Reference

Transcription:

Urinary Incontinence

Treatment Options: 1. Physical Therapy: a conservative early stage treatment for UI, including pelvic floor muscles training known as Kegel exercise. 2. Medications: by means of pharmaceutical drugs ( fesoterodine, tolterodine, oxybutynin,..etc ). 3. devices: absorbent pads, urinary catheters. 4. Surgical procedures. 5. Bulking agents Urethral Injections of impant material.

Treatment Options: Surgical procedures: 1. TVT: Tension-Free transvaginal sling. 2. TOT: Transoburator tape sling. 3. Mini Sling ( mini-arc ) ( TVT-secure) 4. Marshal-Marchetti-Krantz: retropubic suspension / bladder neck suspension 5. Artificial unrinary sphincter.

Treatment Options: Urethral Injections Bulking Agents: Is a minimal surgical procedure providing An alternative in treatment options: The Ideal Bulking agent of choice must include following charecteristics: 1. Biocompatible. 2. Biodegradable. 3. Bio-stable: no deformation after injection. 4. No Migration after implantion. 5. No erosion after implantion. 6. Easy to applicate without the need to apply pressure when injecting.

Treatment Options: Available Bulking Agents for UI: 1. Polytetrafluoroethylene(teflon) : no longer used. 2. Autologous fat: no longer used. 3. Macroplastique: silicone elastomer polydimethylsiloxane suspended in polyvinylpyrrolidone PVP Carrier. It is a permanent implant applied by transurethral technique injection beneath the lining of urethra can cause urethral erosion with irreversable damage in case of failure of procedure procedure must be done in operation room. 4. Contigen: Glutar aldehyde cross linked bovine collagen: it begins degradation within 12 weeks with complete degaradation within 19month, and patient must undergo a skin test to exclude hypersinsensitivity due to collagen ( animal origin ) before one month of the procedure.

Treatment Options: Available Bulking Agents: 5. Bulkamid: 25% polyacrylamide hydrogel, 97% apyrogenic water, is a permanent implant (nonbiodegradable) 6. Durasphere: carbon coated zirconium oxide particles suspended in water soluble B-glucan vehicle, is a permanent implant, upon clinical trials Durasphere migrates from impantation site which might cause permanent urinary retention. 7. Coaptite: calcium hydroxylapatite particles suspended in sodium carboxymethylcellulose, water, glycerin gel form carrier, upon clinical trials the particles becomes deformed, irregular along with migration from injection site resulting in periurethral fibrosis, obstruction, prolapse.

Treatment Options: Available Bulking Agents: 8. Tegress: formrly known as URYX : ethylenevinyl alcohol copolymer suspended in dimethyl sulfoxide: have discontinued sales due to reports of 37% erosion rates. 9. Zuidex: Dextranomere microspheres in cross linked hyaluronic acid carrier. 10.Urodex : DEAE-Sephadex- Dextran positively Charged Dextranomere. Urodex composition: Sodium Hyaluronate cross linked: 17mg DEAE Sephadex Dextran + chagre: 50mg Sodium Chloride: 6.9mg Water for injection: 1.0ml

Urodex designed Technolgy: Why to use Urodex? What is the added Benefits of Urodex? In order to realize the added benefits of Urodex, a summary explaining the designation technology of the product will answer many questions that may arise. 1. In SUI and as the condition is resulting from pelvic floor muscles weakness that leads to insufficient closure of urethra, basically a material that acts as a bulking agent is needed in order to act in increased tissue thickness at injection site that will aid in complete closure when muscles plays its normal role. and accordingly, the material of choice was DEAE-DEXTRAN ( Diethylaminoethyl- Dextran), the choice was based upon that Dextran is a Biocompatible, Biodegradable, non-immunogenic molecule. Dextran: consists of linked glucan with side chains attached to the 3-position of the backbone glucose units, and it is produced by bacterial fermentation process ( nonanimal origin ).

Urodex designed Technolgy: 2. DEAE-Dextran Biomaterial cannot be introduced by injection And as the concept of the products is based upon minimal Surgical procedure a carrier material is needed to carry the DEAE-DEXTRAN to site of implantation, the choice of carrier material was the specially designed cross linked hyaluronic acid Technically adjusted to play the role of a ( carrier ), again the choice was upon that HA is a biocompatible, biodegradable, Non-immunogenic molecule. 3. After that and as a long duration effect is favorable in treatment of SUI the Specially designed cross linking process was applied to DEAE-DEXTRAN to obtain a cross Linked DEAE-DEXTRANOMERE or what is called a DEAE-Sephadex-Dextran, Sephadex Is a trade mark for cross linked dextran, where cross linking process results in a long term Duration of the implant to be degraded gradually.

Urodex designed Technolgy: 4. Finally, a ( fine tuning ) process was created by Biopolymer GmbH Germany to ensure maximum effect results outcome for the product ( Urodex ) to be unique and distinguished in SUI Treatment options, the ( fine tuning ) was made by creating a positive charge on DEAE-Sephadex Dextran which stimulates collagen formation in site of implantation and leading by that for optimum results in treatment of SUI by stimulating tissue regeneration process. Accordingly, DEAE-Sephadex-Dextran is a polycationic cross linked dextran with tissue regeneration stimulating effect. 5. Accordingly, the benefits of Urodex are summarized as following: A. Biocompatible: as the used materials is a natural component of human body tissues, it is non-immunogenic ( non-animal origin ), and biocompatibility is optimal due to formation of fibroblast and collagen fibers that surrounds the microparticles. B. Biodegradable: the used materials are completely degradable with safe clinical profile. C. Long action duration: due to cross linking process that extends up to 5 five years. D. No Migration from implant site: due to positively charged microparticles the positive charge plays a role in ( ancoring ) the implant through inter-cellular interactions leading to fibroblasts and collagen fibers surrounding the implant material as well that microparticles size used ensures no migration. ( safe particel size 80 micron ). E. Stimulation of collagen formation: due to positive charges.

Urodex Kit: Urodex Kit: 4 syringes 1.0ml 2 sterile needles 20G 1 Applicator 1 catheter

Urodex Applicator Special design for minimal invasive and safe implantation Controlled implantation in a 4-position (3, 6, 9, 12) symmetrical placement with injection volume of 1.0ml per position. Periurethral Injection technique.

Urodex Applicator Designed with measurements for implantation in precise site. After measurement of urethra by catheter, transfer the length to the applicator, insert the applicator into urethra to the previosuly marked measurement and inject the implant material. Video is available for procedure.

URODEX Injection Introduce mounted needle in the applicator Important! Opening of the needle in direction upward

The Implantation 1 syringe/1 ml in position 3

The Implantation 1 syringe/1 ml in position 9

The Implantation 1 syringe/1 ml in position 12

The Implantation 1 syringe/1 ml in position 6

Clinical trials

Thank you